As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) ...

Vitamin D also helps clear beta amyloid, a protein that plays a role in Alzheimer’s disease, Merrill points out. This is “the ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Individuals who suffer head trauma from sports, accidents, or other causes often go on to develop neurodegenerative diseases ...

The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...